Radiopharm Theranostics Limited announced it has acquired full intellectual property (IP) ownership to three assets to target diagnosis and treatment of a range of solid tumors. Radiopharm will acquire the patents to three different nanobodies from NanoMab Technology Ltd. (NanoMab), targeting HER-2 (breast cancer), TROP-2 (triple negative breast cancer, or TNBC) and
PTK7 (multiple solid tumours). Nano-mAbs are made using genetically engineered camelid derived single domain antibodies (sdAb), that can be labelled with radioisotopes to diagnose and treat multiple tumor types. Radiopharm has been using NanoMab nanobodies under a licence agreement in its Phase 1 clinical trials and pre-clinical studies. As announced in December, a Phase 1 study investigating the safety, dosimetry and efficacy of the RAD201 asset, targeting HER-2 positive breast cancer subjects, was completed with the Company's collaborators at Shanghai General Hospital and NanoMab. Results from the Phase 1 clinical studies completed to date have indicated the potential to use NanoMab's nanobodies for imaging and treatment of HER-2+ cancers with different medical radioisotopes. Final candidate selection for TROP2 and PTK7 is underway and expected soon.